Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
Stopped early · Phase 2
Conditions studied: Discoid Lupus Erythematosus
In brief
This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).
Key facts
- Study ID
- NCT03958955
- Run by
- LEO Pharma
- People needed
- 27
- Starts
- 2019-07-09
- Expected to finish
- 2020-04-30
- Last updated by the study team
- 2025-03-06
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- LEO Pharma Investigational Site — San Diego, California, United States
- LEO Pharma Investigational Site — Skokie, Illinois, United States
- LEO Pharma Investigational Site — Boston, Massachusetts, United States
- LEO Pharma Investigational Site — Forest Hills, New York, United States
- LEO Pharma Investigational Site — Cincinnati, Ohio, United States
- LEO Pharma Investigational Site — Aarhus, Denmark
- LEO Pharma Investigational site — Hellerup, Denmark
- LEO Pharma Investigational Site — Odense, Denmark
- LEO Pharma Investigational Site — Loiré, France
- LEO Pharma Investigational Site — Nice, France
- LEO Pharma Investigational Site — Paris, France
- LEO Pharma Investigational Site — Toulouse, France
- LEO Pharma Investigational Site — Aachen, Germany
- LEO Pharma Investigational Site — Berlin, Germany
- LEO Pharma Investigational Site — Bochum, Germany
- LEO Pharma Investigational Site — Dresden, Germany
- LEO Pharma Investigational Site — Düsseldorf, Germany
- LEO Pharma Investigational Site — Erlangen, Germany
- LEO Pharma Investigational Site — Oldenburg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.